The Russian Direct Investment Fund (RDIF) and Malaysian pharmaceutical company Duopharma Sdn Bhd have entered into an agreement on the terms of supply of the Sputnik V coronavirus vaccine
“This agreement is only the first step towards establishing a comprehensive bilateral cooperation, which includes not only the supply of the Russian vaccine but also the establishment of Malaysia’s own research facility for its production”, – Russian ambassador to Malaysia Nail Latypov said.
The RDIF specified that the Russian Sputnik V coronavirus vaccine to be supplied to Malaysia will be produced in India, China and South Korea.